The World Health Organization is tracking nine distinct versions of the SARS-CoV-2 virus as of June 25, 2025. Some spread faster. Some might make people sicker. Others could blunt the protection vaccines provide.
One variant, JN.1, carries the official label “variant of interest.” That designation means it has turned up in multiple countries or regions and has the potential to keep spreading. The WHO uses that classification to decide where to aim public health resources. A variant of interest gets watched more closely. Governments and health agencies adjust their responses based on what the WHO flags.
Seven other variants sit one step lower, under the category “under monitoring.” Their names are KP.3, KP.3.1.1, JN.1.18, LP.8.1, NB.1.8.1, XEC, and XFG. These have been found in limited geographic areas so far. But each has shown signs that it could become more contagious or more dangerous. The WHO is not raising alarms yet. It is watching.
The stakes are concrete. Genetic changes in the virus can make it more transmissible. That means more people get infected, faster. Hospitals fill up. Workers call in sick. Supply chains hiccup. The same mutations can increase virulence, meaning the disease itself gets worse for those who catch it. More severe symptoms mean more ICU beds needed, more oxygen, more deaths.
Vaccine effectiveness is the third risk. Some variants evolve in ways that let them slip past the immune protection people built from shots or prior infections. If a variant reduces how well vaccines work, the protection millions of people rely on gets weaker. Booster campaigns may need to be redesigned. Vulnerable populations — the elderly, the immunocompromised — face the highest danger first.
The WHO has been monitoring SARS-CoV-2 evolution continuously since the virus emerged. The agency classifies variants based on genetic changes significant enough that virologists give them separate labels. Not every mutation matters. Some make no real difference. Others shift the virus’s behavior in ways that change the pandemic’s trajectory.
JN.1 earned its “variant of interest” status because it has shown up in enough places and has enough concerning genetic changes to warrant attention. The seven variants under monitoring have not yet met that bar. But they could. The list changes over time. Variants get promoted, downgraded, or dropped as new data comes in.
The practical effect of these classifications is straightforward. Public health authorities use them to decide when to issue travel advisories, when to recommend updated vaccines, when to ramp up genomic surveillance. Hospitals use the information to prepare for potential surges. Drug manufacturers use it to decide which variants to target in next-generation treatments.
The WHO does not announce new variants lightly. Each designation carries weight. It triggers funding decisions, policy shifts, and public communication campaigns. The agency’s goal is to stay ahead of the virus, not chase it.
As of June 25, 2025, the virus is still changing. The WHO is still watching. The nine variants on the current list are the ones that matter right now. That list will change.
